BioSpace News Archive

Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease.

bluebird bio, Inc. is expecting gross proceeds of $120 million with its newly announced public offering of 20,000,000 shares.

Roche’s Tecentriq (atezolizumab) combined with Avastin (bevacizumab) met the primary efficacy endpoint in early-stage hepatocellular carcinoma in the Phase III IMbrave050 study.

Jazz Pharmaceuticals and Zymeworks announced results from a Phase II trial of the latter’s HER2-targeted antibody for metastatic gastroesophageal adenocarcinoma.

Editas announced the sale of its iPSC-derived iNK programs to Shoreline Biosciences. Shoreline also licensed Editas’ SLEEK technology.

MAPS Public Benefit Corporation (“MAPS PBC”), a private biopharmaceutical company dedicated to the development and commercialization of psychedelic medicines, announced Frontiers in Psychiatry has published the first functional neuroimaging study designed to evaluate the impact of MDMA-assisted therapy in participants with post-traumatic stress disorder (“PTSD”).

Nevro Corp. today announced that the company will report its financial results for the fourth quarter and full year ended December 31, 2022 after the market closes on February 16, 2023.

Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results.

Apex Labs Ltd. (APEX or the Company), a pharmaceutical company optimizing the standard of mental health care with psilocybin, is pleased to announce its approval by Health Canada to begin APEX-002-A01-03, the world’s largest take home psilocybin clinical trial approved to date.

Surmodics, Inc. today announced it has received a letter from the U.S. Food and Drug Administration (FDA; the Agency) related to its premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB).